Anaptysbio, INC

AnaptysBio and defendants GlaxoSmithKline have agreed to a post-trial briefing schedule in their Delaware litigation concerning a collaboration agreement.

AnaptysBio has filed IRS Form 8937 to provide tax guidance regarding the recent spin-off of First Tracks Biotherapeutics.

AnaptysBio, Inc. announced a change in its fiscal year-end from December 31 to June 30, effective July 1, 2026.

AnaptysBio reported Q1 2026 financial results, highlighting strong Jemperli royalty growth and providing a business update following the spin-off of First Tracks Biotherapeutics.

AnaptysBio announces the appointment of Christopher M. Murphy as Chief Financial Officer and Owen Hughes as a Class I director, effective May 11, 2026.

AnaptysBio, Inc. has finalized the spin-off of its biopharma operations into the independent entity First Tracks Biotherapeutics, Inc.

AnaptysBio reports first-quarter 2026 financial results, detailing a net loss of $52.9 million and the successful separation of its First Tracks Biotherapeutics business.

AnaptysBio reported a significant increase in collaboration revenue for Q3 2025, driven by Jemperli sales milestones, while advancing plans to separate into two independent public companies by year-end 2026.

AnaptysBio reports increased collaboration revenue and reduced operating loss in Q2 2025, driven by positive rosnilimab data and new partnerships, despite a significant cash burn and a partnered trial setback.

AnaptysBio's Q1 2025 results show increased collaboration revenue driven by royalties, progress in rosnilimab clinical trials, and a new licensing agreement with Vanda Pharmaceuticals.

AnaptysBio's Q3 2024 results show a significant increase in collaboration revenue driven by milestone and royalty payments, alongside ongoing clinical development of key product candidates.

AnaptysBio's Q2 2024 results show increased collaboration revenue and R&D expenses, alongside a net loss, as the company advances its clinical programs.

AnaptysBio amends its 2025 annual report to include details on board composition changes, executive compensation, and related party transactions.

AnaptysBio, a clinical-stage biotechnology company, announced plans to separate into two independent public entities, reporting significant Jemperli sales growth and positive Phase 2b rheumatoid arthritis trial data for rosnilimab.

AnaptysBio achieved key clinical milestones with its lead drug candidate, rosnilimab, and continues to advance its portfolio of immunology therapeutics.

AnaptysBio's 2023 annual report highlights its focus on developing innovative immunology therapeutics, with key updates on its clinical-stage checkpoint agonist programs and strategic collaborations.

AnaptysBio, Inc. Director John P. Schmid acquired 6,030 restricted stock units on June 15, 2026, with full vesting scheduled for June 15, 2026.

AnaptysBio Director John Orwin acquired 6,030 restricted stock units, vesting fully on June 15, 2026.

Director Owen Hughes was granted 11,250 restricted stock units in AnaptysBio, Inc. as part of standard equity compensation.

AnaptysBio CFO Christopher M. Murphy was granted 25,765 restricted stock units as part of an equity compensation plan.

CEO Daniel Faga filed an amendment to a Form 4 to correct the reported number of stock options held.

Director John A. Orwin reports adjustments to stock options following the spin-off of First Tracks.

AnaptysBio, Inc. has announced its 2026 Annual Meeting of Stockholders will be held on August 11, 2026, to elect directors, ratify auditors, vote on executive compensation, and approve an amendment to its equity incentive plan.

AnaptysBio, Inc. has filed a definitive proxy statement with the SEC.

AnaptysBio announces its 2025 Annual Meeting of Stockholders to be held on June 17, 2025, including proposals for director elections, auditor ratification, executive compensation, and an amendment to the 2017 Equity Incentive Plan.

AnaptysBio, Inc. has filed a definitive proxy statement with the SEC.

AnaptysBio announces its 2024 Annual Meeting of Stockholders to be held on June 12, 2024, outlining proposals for director elections, auditor ratification, executive compensation advisory vote, and equity incentive plan amendment.

Point72 Asset Management and Steven A. Cohen have filed a Schedule 13G reporting a 0.2% beneficial ownership stake in AnaptysBio, Inc.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, disclosing beneficial ownership of 6.7% of AnaptysBio, Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in AnaptysBio Inc. following an internal realignment.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported reducing their beneficial ownership in AnaptysBio, Inc. to below the 5% threshold.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander jointly reported a 2.9% beneficial ownership stake in AnaptysBio, Inc. as of December 31, 2025.

First Light Asset Management and its principal, Mathew P. Arens, have filed an amended Schedule 13G, reporting their aggregate beneficial ownership in AnaptysBio Inc. at 3.12%.